Zacks Research Upgrades Axon Enterprise (NASDAQ:AXON) to “Strong-Buy”

Axon Enterprise (NASDAQ:AXON) was upgraded by equities researchers at Zacks Research from a “hold” rating to a “strong-buy” rating in a report released on Tuesday,Zacks.com reports.

A number of other equities research analysts have also issued reports on AXON. Citizens Jmp lowered their target price on Axon Enterprise from $825.00 to $700.00 and set a “market outperform” rating for the company in a research note on Thursday, May 7th. Royal Bank Of Canada lowered their target price on Axon Enterprise from $860.00 to $735.00 and set an “outperform” rating for the company in a research note on Wednesday, February 25th. The Goldman Sachs Group set a $535.00 target price on Axon Enterprise in a research note on Thursday, May 7th. Weiss Ratings upgraded Axon Enterprise from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Friday, May 8th. Finally, TD Cowen lowered their price objective on Axon Enterprise from $950.00 to $825.00 and set a “buy” rating for the company in a research note on Wednesday, April 8th. One analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, Axon Enterprise presently has a consensus rating of “Moderate Buy” and a consensus price target of $712.75.

Axon Enterprise Price Performance

AXON stock opened at $398.44 on Tuesday. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.93 and a current ratio of 2.27. Axon Enterprise has a 1 year low of $339.01 and a 1 year high of $885.91. The firm has a market cap of $32.11 billion, a P/E ratio of 160.02, a price-to-earnings-growth ratio of 7.13 and a beta of 1.44. The stock has a 50-day simple moving average of $421.95 and a 200-day simple moving average of $506.34.

Axon Enterprise (NASDAQ:AXON) last posted its earnings results on Wednesday, May 6th. The biotechnology company reported $1.61 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.60 by $0.01. Axon Enterprise had a return on equity of 3.78% and a net margin of 6.90%.The business had revenue of $807.35 million during the quarter, compared to analyst estimates of $778.91 million. During the same quarter last year, the firm earned $1.47 earnings per share. The company’s revenue for the quarter was up 33.7% compared to the same quarter last year. On average, equities analysts predict that Axon Enterprise will post 1.82 earnings per share for the current fiscal year.

Insider Activity

In other Axon Enterprise news, Director Jeri Williams sold 157 shares of the firm’s stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $490.00, for a total transaction of $76,930.00. Following the completion of the sale, the director owned 1,159 shares in the company, valued at $567,910. This trade represents a 11.93% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Isaiah Fields sold 2,000 shares of the firm’s stock in a transaction that occurred on Friday, February 27th. The shares were sold at an average price of $535.01, for a total value of $1,070,020.00. Following the sale, the insider owned 55,588 shares of the company’s stock, valued at approximately $29,740,135.88. This trade represents a 3.47% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 13,855 shares of company stock worth $7,109,828 over the last quarter. Corporate insiders own 4.20% of the company’s stock.

Institutional Investors Weigh In On Axon Enterprise

A number of hedge funds have recently bought and sold shares of the business. Arkadios Wealth Advisors lifted its holdings in Axon Enterprise by 3.5% during the 1st quarter. Arkadios Wealth Advisors now owns 3,792 shares of the biotechnology company’s stock worth $1,610,000 after buying an additional 127 shares during the last quarter. EverSource Wealth Advisors LLC lifted its holdings in Axon Enterprise by 10.3% during the 1st quarter. EverSource Wealth Advisors LLC now owns 1,736 shares of the biotechnology company’s stock worth $737,000 after buying an additional 162 shares during the last quarter. Empowered Funds LLC lifted its holdings in Axon Enterprise by 90.1% during the 1st quarter. Empowered Funds LLC now owns 6,320 shares of the biotechnology company’s stock worth $2,684,000 after buying an additional 2,996 shares during the last quarter. Evelyn Partners Investment Management LLP lifted its holdings in Axon Enterprise by 42.6% during the 1st quarter. Evelyn Partners Investment Management LLP now owns 1,550 shares of the biotechnology company’s stock worth $658,000 after buying an additional 463 shares during the last quarter. Finally, Evelyn Partners Investment Management Services Ltd lifted its holdings in Axon Enterprise by 18.6% during the 1st quarter. Evelyn Partners Investment Management Services Ltd now owns 862 shares of the biotechnology company’s stock worth $366,000 after buying an additional 135 shares during the last quarter. Institutional investors and hedge funds own 79.08% of the company’s stock.

Axon Enterprise News Roundup

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Axon’s Connected Devices segment is benefiting from strong demand for TASERs, body cameras, and counter-drone products, reinforcing the company’s revenue growth story. Strength in Connected Devices Unit Drives Axon: Can the Momentum Sustain?
• Positive Sentiment: The company is highlighting AI and drone growth as part of its strategy to become a broader “operating system” for public safety, which could expand long-term recurring revenue opportunities. Axon Enterprise touts AI, drone growth in push to be public safety’s operating system
• Positive Sentiment: Investors are also reacting to Axon’s strong Q1 2026 results, which included revenue of $807.35 million and higher full-year revenue growth guidance of 30%–32%, signaling sustained momentum. Should Axon’s Strong Q1 2026 Results and Higher Guidance Require Action From Axon Enterprise (AXON) Investors?
• Neutral Sentiment: Axon’s presentation at the J.P. Morgan Technology, Media and Communications Conference kept management’s growth story in front of investors, but the item itself did not include a major new catalyst. Axon Enterprise, Inc. Presents at J.P. Morgan Conference Transcript
• Neutral Sentiment: Commentary from Jim Cramer framed AXON as a high-multiple stock that may remain sensitive to bond yields and market sentiment, which is a reminder of valuation risk rather than a direct company-specific negative. Jim Cramer on Axon: “I Still Think That This Market Does Not Like High Multiple Stocks”
• Negative Sentiment: One market report noted AXON underperformed some competitors despite gains, suggesting investors may be weighing its rich valuation against the strong growth outlook. Axon Enterprise Inc. stock underperforms Monday when compared to competitors despite daily gains

Axon Enterprise Company Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.